Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVERT: Apixaban for VTE prevention in cancer
NCT02048865Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in venous thromboembolism (VTE) comparing Apixaban with Placebo (2 arms). Primary endpoint: First episode of objectively documented, symptomatic or asymptomatic Venous Thromboembolism (DVT and/or PE) at 7 months. Started Mar 2014; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02048865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048865.